Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

126 results about "Hepcidin" patented technology

Hepcidin is a protein that in humans is encoded by the HAMP gene. Hepcidin is a key regulator of the entry of iron into the circulation in mammals. During conditions in which the hepcidin level is abnormally high, such as inflammation, serum iron falls due to iron trapping within macrophages and liver cells and decreased gut iron absorption. This typically leads to anemia due to an inadequate amount of serum iron being available for developing red blood cells. When the hepcidin level is abnormally low such as in hemochromatosis, iron overload occurs due to increased ferroportin mediated iron efflux from storage and increased gut iron absorption.

Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor

The present invention concerns antibodies specific for the C-terminus of human hepcidin, and related methods and kits for diagnosing and / or treating a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 60 and 84, or, in another embodiment, amino acids 74 and 81, as aligned with the human pre-pro-hepcidin precursor protein, and quantifying the pro-hepcidin and / or mature hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin / mature hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin.
Owner:DRG INTERNATIONAL INC

Biomarker for ovarian and endometrial cancer: hepcidin

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +2

Hepcidin analogues and uses thereof

ActiveUS20160222076A1Hormone peptidesPeptide/protein ingredientsIron loading anemiaIron Overload Disease
The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and / or prevention of a variety of diseases, conditions or disorders, including treatment and / or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
Owner:PROTAGONIST THERAPEUTICS INC

Analogues of hepcidin mimetics with improved in vivo half lives

The present invention provides hepcidin analogues with improved in vivo half-lives, and related pharmaceutical compositions and methods of use thereof.
Owner:PROTAGONIST THERAPEUTICS INC

Expression carrier for black porgy antibiotic peptide Hepcidin and expression product and constructing preparation method

The invention discloses an expressing carrier of black porgy antibiotic peptide Hepcidin, expressing product and preparing method, which is characterized by the following: incorporating E. coliTrc promoter, protein project improving CKS gene and procaryotic expressing carrier pTrc-CKS of histidine tag (His-Tag); connecting to black porgy Hepcidin gene; constructing pTrc-CKS / hepcidin expressing plasmid; possessing P3C enzyme cutting site; fusing six histidine on C end; getting CKS-hepcidin; purifying through C end His-Tag affinity chromatography; getting the purified product; cutting CKS with P3C enzyme in fuse protein; getting the purified Hepcidin.
Owner:XIAMEN UNIV

Treatment of osteoporosis in peri- and post- menopausal women with hepcidin

InactiveUS20100204122A1Treating preventing reducing riskInhibit bone formationOrganic active ingredientsPeptide/protein ingredientsPost menopausalDuring menopause
The present invention is directed to a method of treating, preventing, or reducing the risk of bone deterioration or osteoporosis in a peri- or post-menopausal female subject. The method involves selecting a peri- or post-menopausal female subject in need of treating, preventing, or reducing the risk of bone deterioration or osteoporosis and administering hepcidin to the selected subject under conditions effective to treat, prevent, or reduce the risk of bone deterioration or osteoporosis.
Owner:NEW YORK UNIV

Recombinant human iron-regulatory hormone adenovirus, preparation method and application thereof

The present invention discloses a recombinant human hepcidin adenovirus (Ad-hepc), which contains human hepcidin gene and adenovirus vector. The present invention also discloses a preparation of the recombinant human hepcidin adenovirus and an application thereof. The present invention utilizes defective adenovirus to deliver the human hepcidin gene into the tissue cells of the body, so that the virus can express hepcidin protein in the body of a patient.
Owner:THE HONG KONG POLYTECHNIC UNIV SHENZHEN RES INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products